ClinicalTrials.gg
Not yet recruitingNCT06887075INTRAUpdated Mar 20, 2025

Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation

An interventional study of Blood sample and Geriatric assessment standardized in Chronic Kidney Failure, Frailty and Aging, sponsored by University Hospital, Bordeaux. Not yet recruiting at 3 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.

Planned enrollment
61st of 105
60 · median 70
Started
2025
with 3 others
No phase
55 of 145
10 open now
Primary completion
2027-02
later than 14 of 32 live
Registered
140th of 145
by date
Lead sponsor
6 of 145
University Hospital, Bordeaux

Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 61st largest by planned enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2025, is one of 55 with no phase, reaches primary completion later than 14 of the 32 other live ones, and was the 140th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Kidney Failure, Chronic with a site in France, or all of them as a file.
02

Study summary

Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. A pre-KT frailty phenotype has been found predictive of post-KT complications, but biological mechanisms of frailty are poorly known is these patients. Frailty is associated with chronic low-grade inflammation in the older general population, possibly through the inflammasome pathway. Our main objective is to assess if systemic activation of inflammasomes is associated with frailty in older candidates to KT.

Read the detailed description

Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. Chronic low-grade inflammation is a hallmark of biological aging and is associated with age-related diseases and frailty. Frailty is conceptually defined as an agerelated reduction in physiological reserve increasing vulnerability to stressors. A pre-KT frailty phenotype is associated with post-KT complications, including re-hospitalizations, delayed graft function, delirium and 5-year mortality. Taking pre-KT inflammation into account (serum level of CRP, IL6, sTNFR1) improves prediction of mortality on KT waiting-list, independently of comorbidity.

Molecular and cellular pathways of this inflammation are poorly known, and may involve inflammasomes. Inflammasomes are intra-cellular protein complexes whose assembly, upon stress signals, triggers maturation and release of pro-inflammatory cytokines named interleukine (IL)-1 and IL-18. Inflammasomes are involved in locomotor, cognitive and immune aging in mice, and systemic expression of inflammasomes genes is associated with mortality in older humans. Data is lacking about systemic activation of inflammasomes in older patients with end-stage kidney disease. Our main objective is to assess if pre-KT systemic activation of inflammasomes is associated with frailty in older candidates to KT.

We will measure systemic activation of inflammasomes in peripheral blood of older candidates to KT using cytokine bead-based multiplex assay, Single Molecule Array, intra-cytoplasmic staining, flow cytometry and RT-qPCR in peripheral blood mononuclear cells. Frailty will be measured using validated standardized criteria. A frailty phenotype is defined by at least 3 of the following criteria:

weight loss, exhaustion, muscle weakness, low physical activity, low gait speed.

03

Conditions studied

  • Chronic Kidney Failure
  • Frailty
  • Aging
  • Inflammation

Keywords

  • Older persons
  • End-stage kidney disease
  • Kidney transplantation
  • Immune aging
  • Chronic low-grade inflammation
  • Inflammasomes
  • Frailty
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 70

    • Patient candidate to kidney transplantation (during assessment for inscription on the waiting-list, or during waiting time after effective inscription), without absolute
    • Free, informed and written consent signed by the participant and the investigator (at the latest, on the day of inclusion and before any examination required by the research).
    • Person affiliated or beneficiary of a social security scheme

Exclusion criteria

  • Inclusion in an industrial study refusing co-inclusion in our study

    • Person under guardianship, assisted decision-making or under temporary guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Frail Patients

    Frailty will be measured clinically using reference criteria in the general population and validated in Kidney Transplantation (KT), i.e. predictive of post-KT complications: delayed recovery of graft function, graft function, early re-hospitalization, occurrence of post-operative confusion, mortality. Fragile patients present at least 3 out of 5 criteria

    Biological: Blood sample · Behavioral: Geriatric assessment standardized

  • Active comparator
    non frail patients

    Patients will be considered non-fragile if they present 0 to 2 criteria

    Biological: Blood sample · Behavioral: Geriatric assessment standardized

Interventions

  • BiologicalBlood sample

    * Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence * Serum inflammatory markers : CRP, IL-6, MCP-1, TNF, sTNFR1 * Single Molecule Array for IL1 and LUMINEX for IL18 in patient's sera * RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells * Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry

  • BehavioralGeriatric assessment standardized

    * Exhaustion (2 standardized questions) * Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ) * 4-meters gait speed, with sex and height-specific cutoffs * Handgrip strength, measured using a dynamometer, with sex and BMI-sp Comorbidity (CIRS-G score ) * Screening for intrinsic capacity decline (first step of ICOPE program, adapted to the study, ) * Physical performance (SPPB score ) * Cognitive functions (MoCA score ), * Depression (GDS-15 score ), * Nutrition (MNA score ) * Sensory functions (Snellen test for vision, HHIES questionnaire for hearing) -- Dependency in activities of daily living (ADL and IADL scores)

06

What researchers measure

Primary outcomes

  1. IL1

    Single Molecule Array for IL1

    Time frame: at recruitment (up to 30 days)

  2. IL18

    LUMINEX for IL18 in patient's sera

    Time frame: at recruitment (up to 30 days)

  3. inflammasomes genes

    RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells

    Time frame: at recruitment (up to 30 days)

  4. inflammasome platform

    Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry

    Time frame: at recruitment (up to 30 days)

  5. Weight

    Frailty phenotype : Weight loss (unintentional, \>4,5 kg during past year)

    Time frame: at enrollment (Day 0), at recruitment (up to 30 days)

  6. Activity

    Frailty phenotype : Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ)

    Time frame: at enrollment (Day 0), at recruitment (up to 30 days)

  7. Gait

    Frailty phenotype : 4-meters gait speed, with sex and height-specific cutoffs

    Time frame: at enrollment (day 0), at recruitment (up to 30 days)

  8. Handgrip strength

    Frailty phenotype : Handgrip strength, measured using a dynamometer, with sex and BMI-specific cutoffs

    Time frame: at enrollment (day 0), at recruitment (up to 30 days)

Secondary outcomes

  1. Comorbidity

    Comorbidity : Cumulative Illness Rating Scale (CIRS-G score)

    Time frame: at recruitment (up to 30 days)

  2. decline

    Screening for intrinsic capacity decline : first step of ICOPE program, adapted to the study

    Time frame: at recruitment (up to 30 days)

  3. Physical performance

    Physical performance : Short Physical Performance Battery (SPPB) score. The SPPB (Short Physical Performance Battery) is the sum of scores on three criteria: the balance test, the walking speed test and the chair lift test. This test assesses an individual's physical performance. The sum of the scores for all the tests gives an overall performance score. A score below 8 indicates a risk of sarcopenia (or age-related muscular dystrophy).

    Time frame: at recruitment (up to 30 days)

  4. Cognitive functions

    Cognitive functions : Score Montreal Cognitive Assessment (MoCA) score The Montreal Cognitive Assessement (MoCA) is the most sensitive rapid assessment test, providing the most comprehensive evaluation (attention, concentration, executive functions, memory, language, capacitive-vesuo-constructive, abstraction, calculation, orientation) cognitive functions. It is tending to replace the MMSE in clinical practice. A score of 26 (25 if cultural level ≤3 = primary diploma = CEP) is considered abnormal.

    Time frame: at recruitment (up to 30 days)

  5. Depression

    Depression : Geriatric Depression Scale (GDS-15 score) 0 - 5 points: normal 5-10 points: mild to moderate depression 11-15 points: severe depression

    Time frame: at recruitment (up to 30 days)

  6. Nutrition

    Nutrition : Mini Nutritional Assessment (MNA score) * 12-14 points: MNA score indicates normal nutritional status. * 8-11 points: the MNA score indicates a risk of malnutrition. * 0-7 points: MNA score indicates malnutrition.

    Time frame: at recruitment (up to 30 days)

  7. Snellen test

    Sensory functions : Snellen test for vision

    Time frame: at recruitment (up to 30 days)

  8. ADL

    Dependency in activities of daily living : Activities of Daily Living ADL The original ADL scale scores each of the 6 items in 0/1, with 1 corresponding to independence and 0 to dependence. The total score ranges from 0 to 6. An overall score can be calculated, ranging from 0 (totally dependent) to 6 (best possible independence).

    Time frame: at recruitment (up to 30 days)

  9. Immunophenotyping

    Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence

    Time frame: at recruitment (up to 30 days)

  10. CRP

    Serum inflammatory markers : CRP

    Time frame: at recruitment (up to 30 days)

  11. IL-6

    Serum inflammatory markers : IL-6

    Time frame: at recruitment (up to 30 days)

  12. MCP-1

    Serum inflammatory markers : MCP-1

    Time frame: at recruitment (up to 30 days)

  13. TNF

    Serum inflammatory markers : TNF

    Time frame: at recruitment (up to 30 days)

  14. sTNFR1

    Serum inflammatory markers : sTNFR1

    Time frame: at recruitment (up to 30 days)

  15. HHIES questionnaire

    Sensory functions : Hearing Handicap Inventory for the Elderly Screening (HHIES) questionnaire for hearing. The higher the score, the greater the likelihood of hearing loss

    Time frame: at recruitment (up to 30 days)

  16. IADL

    Dependency in activities of daily living : IADL scores

    Time frame: at recruitment (up to 30 days)

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Feb 2027, 22 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 22 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Mar 20, 2025
StartEst.
Apr 15, 2025
Primary completionEst.
Feb 15, 2027
CompletionEst.
Feb 15, 2027
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06887075
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Apr 15, 2025 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Florent GUERVILLE, MD
Contact
florent.guerville@chu-bordeaux.fr
05 57 65 65 53 ext. +33
Florent GUERVILLE, MD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion